News – Page 871 – Endpoints News

A $1B-plus drug stumbles into another big PhIII setback — this time flunking futility test — as FDA hold remains ...

6 years ago

Drug-drug interactions: FDA issues guidance on clinical, in vitro studies

6 years ago

Kura co-founder heads to Asian multi-national as biotech eyes the goal posts for lead drug

6 years ago

FDA waves Epizyme's $186K rare cancer drug through to market — now get ready for the second act

6 years ago

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

6 years ago

2019 a 'transformative year' for pharma M&A. Is that a good thing?

6 years ago

Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron's CBO hops ship to lead startup

6 years ago

British Heart Foundation unveils shortlist for £30M research award; Onconova scraps China partnership

6 years ago

Merck KGaA spinout gets first funding to bring dual-acting cancer molecules into the clinic

6 years ago

Eli Lilly’s $1.6B cancer drug failed to spark even the slightest positive gain for patients in its 1st PhIII

6 years ago

Amgen augments Asia foothold by taking over Astellas joint venture in Japan

6 years ago

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

6 years ago

The FDA has devalued the gold standard on R&D. And that threatens everyone in drug development

6 years ago

Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country

6 years ago

Pascal Soriot and AstraZeneca commit to zero-carbon by 2025, carbon-neutral by 2030. Where's the rest of Pharma?

6 years ago

New players are jumping into the scramble to develop a vaccine as pandemic panic spreads fast

6 years ago

Fresh trial data fortify position of Roche's oral therapy in spinal muscular atrophy battleground

6 years ago

Wuhan virus outbreak triggers inevitable small-biotech rally

6 years ago

Brexit fears, Woodford woes overshadowed UK biotech and cut 2019 financing by almost half

6 years ago

Blueprint Medicines potentially delays Ayvakit decision; Control beats treatment in mesothelioma trial

6 years ago

Transitional leaders take charge as FDA begins PhIII of OND reorganization

6 years ago

Chicago investor devises £250M deal as real estate grows with UK's biotech sector

6 years ago

Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into ...

6 years ago

NICE stays sour on AstraZeneca's Tagrisso

6 years ago

First page Previous page 868 869 870871872 873 874 Next page Last page